GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Harvard Bioscience Inc (NAS:HBIO) » Definitions » ROE %

Harvard Bioscience (Harvard Bioscience) ROE % : -9.87% (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Harvard Bioscience ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Harvard Bioscience's annualized net income for the quarter that ended in Dec. 2023 was $-7.3 Mil. Harvard Bioscience's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $73.7 Mil. Therefore, Harvard Bioscience's annualized ROE % for the quarter that ended in Dec. 2023 was -9.87%.

The historical rank and industry rank for Harvard Bioscience's ROE % or its related term are showing as below:

HBIO' s ROE % Range Over the Past 10 Years
Min: -22   Med: -5.2   Max: 2.48
Current: -4.62

During the past 13 years, Harvard Bioscience's highest ROE % was 2.48%. The lowest was -22.00%. And the median was -5.20%.

HBIO's ROE % is ranked worse than
54.99% of 811 companies
in the Medical Devices & Instruments industry
Industry Median: 0.29 vs HBIO: -4.62

Harvard Bioscience ROE % Historical Data

The historical data trend for Harvard Bioscience's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harvard Bioscience ROE % Chart

Harvard Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.70 -9.86 -0.36 -12.23 -4.70

Harvard Bioscience Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.24 3.40 -5.24 -6.62 -9.87

Competitive Comparison of Harvard Bioscience's ROE %

For the Medical Instruments & Supplies subindustry, Harvard Bioscience's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harvard Bioscience's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's ROE % distribution charts can be found below:

* The bar in red indicates where Harvard Bioscience's ROE % falls into.



Harvard Bioscience ROE % Calculation

Harvard Bioscience's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-3.415/( (72.22+73.074)/ 2 )
=-3.415/72.647
=-4.70 %

Harvard Bioscience's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-7.272/( (74.286+73.074)/ 2 )
=-7.272/73.68
=-9.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Harvard Bioscience  (NAS:HBIO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-7.272/73.68
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-7.272 / 112.612)*(112.612 / 138.5505)*(138.5505 / 73.68)
=Net Margin %*Asset Turnover*Equity Multiplier
=-6.46 %*0.8128*1.8804
=ROA %*Equity Multiplier
=-5.25 %*1.8804
=-9.87 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-7.272/73.68
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-7.272 / -4.412) * (-4.412 / 1.128) * (1.128 / 112.612) * (112.612 / 138.5505) * (138.5505 / 73.68)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.6482 * -3.9113 * 1 % * 0.8128 * 1.8804
=-9.87 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Harvard Bioscience ROE % Related Terms

Thank you for viewing the detailed overview of Harvard Bioscience's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Harvard Bioscience (Harvard Bioscience) Business Description

Traded in Other Exchanges
Address
84 October Hill Road, Holliston, MA, USA, 01746
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life science and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.
Executives
James W Green director, officer: Chief Executive Officer 12525 CHADRON AVENUE, HAWTHORNE CA 90250
Alan I Edrick director 20200 SUNBURST STREET, CHATSWORTH CA 91311
Jennifer Cote officer: Interim CFO C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Bertrand Loy director C/O ENTEGRIS, INC., 129 CONCORD RD, BILLERICA MA 01821
Thomas W Loewald director 81 WYMAN STREET, WALTHAM MA 02451
John F Kennedy director C/O NET PERCEPTIONS INC, 7700 FRANCE AVE. SOUTH, EDINA MN 55435
Katherine A. Eade director C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Susan M. Steele director C/O HILL INTERNATIONAL, INC., 2005 MARKET ST., 17TH FLOOR, PHILADELPHIA PA 19103
Kenneth Fletcher Olson officer: Chief Operating Officer C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Michael A. Rossi officer: Chief Financial Officer C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Yash Singh officer: Executive Vice President C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Jeffrey Duchemin officer: Chief Executive Officer 14 EASTLAND TERRACE, HAVERHILL MA 01830
Kamalam Unninayar officer: Chief Financial Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Robert E. Gagnon officer: Chief Financial Officer C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493
George Uveges director C/O MFIC CORPORATION, 30 OSSIPEE ROAD, NEWTON MA 02464

Harvard Bioscience (Harvard Bioscience) Headlines